Skip to main content
logo
Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
30.81
-0.37 (-1.19%)
At close: Jul 24, 2026, 4:00 PM EDT
30.91
+0.10 (0.31%)
After-hours: Jul 24, 2026, 7:34 PM EDT

Teva Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
1,5661,418-1,959-615-2,499456
Depreciation & Amortization
9991,0021,0591,1531,3081,330
Stock-Based Compensation
166157123121124119
Other Adjustments
3164382,4597811,302594
Change in Receivables
-78-----
Changes in Inventories
-93152166-147-163380
Changes in Accounts Payable
-144-----
Changes in Other Operating Activities
-1,635-1,366-435-721,355-1,701
Operating Cash Flow
1,7141,6491,2471,3681,590798
Operating Cash Flow Growth
35.39%32.24%-8.85%-13.96%99.25%-34.38%
Capital Expenditures
-542-501-498-526-548-562
Sale of Property, Plant & Equipment
5976836872483
Purchases of Investments
-46-57-71-46-1-47
Cash Acquisitions
---15--7-
Other Investing Activities
1,2531,2191,2931,4721,1401,649
Investing Cash Flow
7657377929686561,523
Short-Term Debt Issued
---700-700
Short-Term Debt Repaid
----700--700
Long-Term Debt Issued
2,2982,298-2,451-4,974
Long-Term Debt Repaid
-2,767-4,112-1,641-4,152-1,369-7,140
Net Long-Term Debt Issued (Repaid)
-469-1,814-1,641-1,701-1,369-2,166
Other Financing Activities
75-337-150-212-118-6
Financing Cash Flow
-394-2,151-1,791-1,913-1,487-2,172
Effect of Exchange Rate Changes on Cash and Cash Equivalents
-4121-174-30-123-128
Net Cash Flow
2,0442567439363621
Free Cash Flow
1,1721,1487498421,042236
Free Cash Flow Growth
53.20%53.27%-11.04%-19.19%341.52%-63.01%
FCF Margin
6.76%6.65%4.53%5.31%6.98%1.49%
Free Cash Flow Per Share
1.000.990.660.750.940.21
Levered Free Cash Flow
-320-1,117-2,988-1,852-1,863-2,302
Unlevered Free Cash Flow
1,1861,761-170.52836.14201.62612.05
SEC Filings: 10-K · 10-Q